Sartorius acquired the Swedish company that specializes in data analytics software for biopharmaceutical development and manufacturing.
On April 3, 2017 Sartorius Stedim Biotech (SSB) announced that it has acquired Umetrics, a specialized provider of data analytics software for development and manufacturing processes. SSB has been a cooperation partner of Umetrics since the end of 2012, distributing and co-marketing their software to players in the biopharmaceutical industry. Umetrics is headquartered in Malmö, Sweden and employs approximately 50 people. Sartorius purchased the company for $72.5 million.
Umetrics software has applications in critical process steps of biopharmaceutical manufacture and development. These steps include cell culture processes and specific purification steps. Applying multivariate data analysis on parameters, such as glucose and lactate, allows process variations and their causes can be displayed in real time. Additionally, design of experiment software permits critical process parameters to be identified and quantified as well as development cycles to be considerably shortened.
Source: Sartorius Stedim Biotech
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.